76.6 F
New York
Saturday, July 2, 2022

Recro Pharma [NASDAQ: REPH] Inks Development Deal with Astex Pharmaceuticals

Must read

Recro Pharma, Inc. [NASDAQ: REPH] has inked a development agreement with Astex Pharmaceuticals, Inc. The firm is delighted to add the firm to the list of CDMO customers. Recro Pharma has gained recognition as a contract development and manufacturing organization (CDMO) committed to resolving multifaceted formulation and manufacturing trials for firms developing oral solid dose drug products

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Shares of Recro Pharma soared 1.58% as it gained +0.04 during the pre-market trading session of Tuesday. The shares of the firm have fluctuated between the 52-week low and high range of $1.49 and $5.82, respectively. REPH’s share has surged 69.80% from its 52-week low and plunged -56.53% from its 52-week high. Additionally, Recro Pharma has a total market capitalization of $69.83 million at the time of writing.

Recro Pharma stated that the help it has been involved to offer signifies the type of durable, trusted relationship it works every day to build with our customers. Furthermore, the firm is looking forward to an ever-expanding corporation and hoped for the success of Astex.

More articles

Latest article

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam